Immunohistochemical expression and serum level of survivin protein in colorectal cancer patients

Jakubowska,Katarzyna; Pryczynicz,Anna; Dymicka‑Piekarska,Violetta; Famulski,Waldemar; Guzińska‑Ustymowicz,Katarzyna

doi:10.3892/ol.2016.5075

Immunohistochemical expression and serum level of survivin protein in colorectal cancer patients

Authors:
- Katarzyna Jakubowska
- Anna Pryczynicz
- Violetta Dymicka‑Piekarska
- Waldemar Famulski
- Katarzyna Guzińska‑Ustymowicz
View Affiliations

Affiliations: Department of General Pathomorphology, Medical University of Białystok, Białystok 15‑269, Poland, Department of Clinical Laboratory Diagnostics, Medical University of Białystok, Białystok 15‑269, Poland, Department of Medical Pathomorphology, Medical University of Białystok, Białystok 15‑269, Poland
Published online on: September 1, 2016 https://doi.org/10.3892/ol.2016.5075
Pages: 3591-3597

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Survivin is one of the apoptosis-related inhibitors that is associated with a more aggressive behavior and a poor prognosis in numerous types of malignancies, including colorectal cancer (CRC). The objective of the present study was to perform immunohistochemical tissue analysis of survivin expression and serum analysis of survivin levels in CRC patients. The study group consisted of 55 CRC patients. Survivin expression was assessed by immunohistochemistry in 38 patients using monoclonal antibodies. Color reactions were observed in the nucleus and cytoplasm of the cancer cells. The expression was defined based on the H‑score method. The level of survivin was determined using the enzyme-linked immunosorbent assay method. A positive immunoreaction was observed in the tumor tissues of 84.2% (32/38) of patients with CRC, consisting of nuclear (63.2%; 24/38) and cytoplasmic (81.6%; 31/38) expression. The survivin nuclear expression was associated with tumor mass location and the presence of distant metastases (P=0.048 and P=0.026, respectively). Survivin was detected in the sera of 38.2% (21/55) of CRC patients and in 81.8% (18/22) of healthy individuals. Serum protein levels were found to correlate with hematocrit (P=0.035), hemoglobin (P=0.008) and albumin (P=0.045), but not with any of the investigated clinicopathological parameters. The immunohistochemical positive reaction of survivin in the nuclei of cancer cells may condition their proliferative capacity, which is associated with higher risk of developing metastatic foci. Thus, the present study suggests that the expression of survivin may have diagnostic implications in cancer of the colon and thus requires further research. By contrast, the survivin serum level in CRC patients appears to be diagnostically ineffectual for clinical use.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M and Yasui Y: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 93:1054–1061. 2001. View Article : Google Scholar : PubMed/NCBI
3	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
4	Walczak H and Krammer PH: The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 256:58–66. 2000. View Article : Google Scholar : PubMed/NCBI
5	Thomadaki H and Scorilas A: BCL2 family of apoptosis-related genes: Functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 43:1–67. 2006. View Article : Google Scholar : PubMed/NCBI
6	Sträter J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T and Möller P: Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: Clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut. 54:661–665. 2005. View Article : Google Scholar : PubMed/NCBI
7	Korkolopoulou P, Saetta AA, Levidou G, Gigelou F, Lazaris A, Thymara I, Scliri M, Bousboukea K, Michalopoulos NV, Apostolikas N, et al: c-FLIP expression in colorectal carcinomas: Association with Fas/FasL expression and prognostic implications. Histopathology. 51:150–156. 2007. View Article : Google Scholar : PubMed/NCBI
8	Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH and Galle PR: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med. 2:1361–1366. 1996. View Article : Google Scholar : PubMed/NCBI
9	Deveraux QL, Stennicke HR, Salvesen GS and Reed JC: Endogenous inhibitors of caspases. J Clin Immunol. 19:388–398. 1999. View Article : Google Scholar : PubMed/NCBI
10	Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O and Margolis RL: Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell. 6:183–189. 2000. View Article : Google Scholar : PubMed/NCBI
11	Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, et al: An IAP-IAP complex inhibits apoptosis. J Biol Chem. 279:34087–34090. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
13	Mahotka C, Wenzel M, Springer E, Gabbert HE and Gerharz CD: Survivin-deltaEx3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 59:6097–6102. 1999.PubMed/NCBI
14	Hamilton SR and Aaltonen LA: World Health Organization Classification of TumoursPathology and Genetics of Tumours of the Digestive System. IARC Press; Lyon: pp. 1042000
15	Kalliakmanis JG, Kouvidou Ch, Latoufis C, Kouvatseas G, Anagnostakis D, Papatheodoridis G, Koskinas J and Archimandritis A: Survivin expression in colorectal carcinomas: Correlations with clinicopathological parameters and survival. Dig Dis Sci. 55:2958–2964. 2010. View Article : Google Scholar : PubMed/NCBI
16	Choi J and Chang H: The expression of MAGE and SSX, and correlation of COX2, VEGF, and survivin in colorectal cancer. Anticancer Res. 32:559–564. 2012.PubMed/NCBI
17	Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ and Shibata D: Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 10:188–193. 2011. View Article : Google Scholar : PubMed/NCBI
18	Xi RC, Biao WS and Gang ZZ: Significant elevation of survivin and livin expression in human colorectal cancer: Inverse correlation between expression and overall survival. Onkologie. 34:428–432. 2011. View Article : Google Scholar : PubMed/NCBI
19	Ponnelle T, Chapusot C, Martin L, Bouvier AM, Plenchette S, Faivre J, Solary E and Piard F: Cellular localisation of survivin: Impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol. 131:504–510. 2005. View Article : Google Scholar : PubMed/NCBI
20	Shintani M, Sangawa A, Yamao N and Kamoshida S: Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma. Int J Clin Exp Pathol. 6:2919–2927. 2013.PubMed/NCBI
21	Qi G, Tuncel H, Aoki E, Tanaka S, Oka S, Kaneko I, Okamoto M, Tatsuka M, Nakai S and Shimamoto F: Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep. 22:557–562. 2009.PubMed/NCBI
22	McKenzie JA, Liu T, Goodson AG and Grossman D: Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res. 70:7927–7937. 2010. View Article : Google Scholar : PubMed/NCBI
23	Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY, Pollack A, Zhang Y, Zietman AL, Shipley WU and Chakravarti A: Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys. 78:1095–1103. 2010. View Article : Google Scholar : PubMed/NCBI
24	Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB and Mo XB: Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol. 105:520–528. 2012. View Article : Google Scholar : PubMed/NCBI
25	Xiaoyuan C, Longbang C, Jinghua W, Xiaoxiang G, Huaicheng G, Qun Z and Haizhu S: Survivin: A potential prognostic marker and chemoradiotherapeutic target for colorectal cancer. Ir J Med Sci. 179:327–335. 2010. View Article : Google Scholar : PubMed/NCBI
26	Shen W, Tu JK, Wang XH and Fu ZX: Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. Oncol Rep. 24:1285–1290. 2010.PubMed/NCBI
27	Li JH, He WJ and He YJ: Expression and clinical significance of Survivin and Livin in DukesoB colorectal cancer. Ai Zheng. 26:547–551. 2007.(In Chinese). PubMed/NCBI
28	Lee YY, Yu CP, Lin CK, Nieh S, Hsu KF, Chiang H and Jin JS: Expression of survivin and cortactin in colorectal adenocarcinoma: Association with clinicopathological parameters. Dis Markers. 26:9–18. 2009. View Article : Google Scholar : PubMed/NCBI
29	Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, Miura M, Akahane K and Shiraki K: Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene. 19:3225–3234. 2000. View Article : Google Scholar : PubMed/NCBI
30	Yagihashi A, Asanuma K, Nakamura M, Araya J, Mano Y, Torigoe T, Kobayashi D and Watanabe N: Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin Chem. 47:1729–1731. 2001.PubMed/NCBI
31	Wang YQ, Zhang HH, Liu CL, Xia Q, Wu H, Yu XH and Kong W: Correlation between auto-antibodies to survivin and MUC1 variable number tandem repeats in colorectal cancer. Asian Pac J Cancer Prev. 13:5557–5562. 2012. View Article : Google Scholar : PubMed/NCBI
32	Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K and Rieber EP: Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 60:1815–1817. 2000.PubMed/NCBI